Point-Counterpoint Q&A w/ Dr. Lin: Oncotype Dx Genomic Prostate Score in Active Surveillance

Daniel W. Lin, MD, and E. David Crawford, MD, discuss several follow-up questions from Dr. Lin’s presentation on the Canary PASS study. The two examine the limitations of the trial, as well as how well it represents the population of men going on active surveillance. They also cover the value of measuring PSA density in active surveillance as a predictor of adverse pathology, the value of active vs. inactive surveillance in prostate cancer treatment, as well as limitations and inconsistency in biopsies in active surveillance patients. They also discuss the potential future decrease of radical prostatectomies with the advent of focal therapies that have recently been approved or may be approved in the next five to ten years.